vs
AtriCure, Inc.（ATRC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是AtriCure, Inc.的1.6倍（$219.9M vs $140.5M），AtriCure, Inc.同比增速更快（13.1% vs 2.0%），AtriCure, Inc.自由现金流更多（$18.4M vs $16.8M），过去两年AtriCure, Inc.的营收复合增速更高（13.6% vs 8.0%）
AtriCure是一家专注于心房颤动及相关心脏病症治疗的医疗设备企业，研发并生产创新外科手术工具与疗法，主要服务北美、欧洲、亚太地区的医院、心脏外科中心及医疗机构，为微创心脏手术提供高效可靠的适配解决方案。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
ATRC vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.6倍
$140.5M
营收增速更快
ATRC
高出11.1%
2.0%
自由现金流更多
ATRC
多$1.6M
$16.8M
两年增速更快
ATRC
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $140.5M | $219.9M |
| 净利润 | — | $-2.2M |
| 毛利率 | 75.0% | 71.1% |
| 营业利润率 | 1.8% | 0.2% |
| 净利率 | — | -1.0% |
| 营收同比 | 13.1% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | $0.04 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRCOFIX
| Q4 25 | $140.5M | $219.9M | ||
| Q3 25 | $134.3M | $205.6M | ||
| Q2 25 | $136.1M | $203.1M | ||
| Q1 25 | $123.6M | $193.6M | ||
| Q4 24 | $124.3M | $215.7M | ||
| Q3 24 | $115.9M | $196.6M | ||
| Q2 24 | $116.3M | $198.6M | ||
| Q1 24 | $108.9M | $188.6M |
净利润ATRCOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $-267.0K | $-22.8M | ||
| Q2 25 | $-6.2M | $-14.1M | ||
| Q1 25 | $-6.7M | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $-7.9M | $-27.4M | ||
| Q2 24 | $-8.0M | $-33.4M | ||
| Q1 24 | $-13.3M | $-36.0M |
毛利率ATRCOFIX
| Q4 25 | 75.0% | 71.1% | ||
| Q3 25 | 75.5% | 72.2% | ||
| Q2 25 | 74.5% | 68.7% | ||
| Q1 25 | 74.9% | 62.8% | ||
| Q4 24 | 74.5% | 69.0% | ||
| Q3 24 | 74.9% | 68.7% | ||
| Q2 24 | 74.7% | 67.8% | ||
| Q1 24 | 74.7% | 67.5% |
营业利润率ATRCOFIX
| Q4 25 | 1.8% | 0.2% | ||
| Q3 25 | 0.2% | -8.3% | ||
| Q2 25 | -4.5% | -7.9% | ||
| Q1 25 | -4.8% | -25.2% | ||
| Q4 24 | -11.7% | -5.3% | ||
| Q3 24 | -6.4% | -9.6% | ||
| Q2 24 | -6.2% | -12.5% | ||
| Q1 24 | -10.0% | -15.6% |
净利率ATRCOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | -0.2% | -11.1% | ||
| Q2 25 | -4.5% | -6.9% | ||
| Q1 25 | -5.5% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | -6.8% | -13.9% | ||
| Q2 24 | -6.9% | -16.8% | ||
| Q1 24 | -12.2% | -19.1% |
每股收益（稀释后）ATRCOFIX
| Q4 25 | $0.04 | $-0.05 | ||
| Q3 25 | $-0.01 | $-0.57 | ||
| Q2 25 | $-0.13 | $-0.36 | ||
| Q1 25 | $-0.14 | $-1.35 | ||
| Q4 24 | $-0.33 | $-0.76 | ||
| Q3 24 | $-0.17 | $-0.71 | ||
| Q2 24 | $-0.17 | $-0.88 | ||
| Q1 24 | $-0.28 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.4M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $491.9M | $450.0M |
| 总资产 | $654.2M | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ATRCOFIX
| Q4 25 | $167.4M | $82.0M | ||
| Q3 25 | $147.9M | $62.9M | ||
| Q2 25 | $117.8M | $65.6M | ||
| Q1 25 | $99.9M | $58.0M | ||
| Q4 24 | $122.7M | $83.2M | ||
| Q3 24 | $130.3M | $30.1M | ||
| Q2 24 | $114.0M | $26.4M | ||
| Q1 24 | $106.0M | $27.0M |
总债务ATRCOFIX
| Q4 25 | — | — | ||
| Q3 25 | $61.9M | $157.2M | ||
| Q2 25 | $61.9M | $157.0M | ||
| Q1 25 | $61.9M | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | $61.9M | $118.5M | ||
| Q2 24 | $61.9M | $118.0M | ||
| Q1 24 | $61.9M | $118.2M |
股东权益ATRCOFIX
| Q4 25 | $491.9M | $450.0M | ||
| Q3 25 | $476.5M | $442.5M | ||
| Q2 25 | $464.5M | $458.3M | ||
| Q1 25 | $454.6M | $458.3M | ||
| Q4 24 | $461.0M | $503.1M | ||
| Q3 24 | $465.0M | $525.9M | ||
| Q2 24 | $462.1M | $546.0M | ||
| Q1 24 | $456.3M | $570.3M |
总资产ATRCOFIX
| Q4 25 | $654.2M | $850.6M | ||
| Q3 25 | $635.4M | $832.6M | ||
| Q2 25 | $608.8M | $837.2M | ||
| Q1 25 | $591.6M | $823.1M | ||
| Q4 24 | $609.3M | $893.3M | ||
| Q3 24 | $615.1M | $867.9M | ||
| Q2 24 | $597.3M | $882.0M | ||
| Q1 24 | $591.6M | $906.0M |
负债/权益比ATRCOFIX
| Q4 25 | — | — | ||
| Q3 25 | 0.13× | 0.36× | ||
| Q2 25 | 0.13× | 0.34× | ||
| Q1 25 | 0.14× | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | 0.13× | 0.23× | ||
| Q2 24 | 0.13× | 0.22× | ||
| Q1 24 | 0.14× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $20.0M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $18.4M | $16.8M |
| 自由现金流率自由现金流/营收 | 13.1% | 7.6% |
| 资本支出强度资本支出/营收 | 1.1% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $48.3M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流ATRCOFIX
| Q4 25 | $20.0M | $27.7M | ||
| Q3 25 | $26.7M | $12.4M | ||
| Q2 25 | $21.6M | $11.6M | ||
| Q1 25 | $-11.0M | $-18.4M | ||
| Q4 24 | $5.8M | $23.7M | ||
| Q3 24 | $20.0M | $11.7M | ||
| Q2 24 | $7.4M | $9.0M | ||
| Q1 24 | $-21.0M | $-18.6M |
自由现金流ATRCOFIX
| Q4 25 | $18.4M | $16.8M | ||
| Q3 25 | $24.1M | $2.5M | ||
| Q2 25 | $19.0M | $4.5M | ||
| Q1 25 | $-13.2M | $-25.1M | ||
| Q4 24 | $3.1M | $15.2M | ||
| Q3 24 | $16.4M | $6.3M | ||
| Q2 24 | $5.0M | $-360.0K | ||
| Q1 24 | $-23.8M | $-29.1M |
自由现金流率ATRCOFIX
| Q4 25 | 13.1% | 7.6% | ||
| Q3 25 | 18.0% | 1.2% | ||
| Q2 25 | 13.9% | 2.2% | ||
| Q1 25 | -10.7% | -13.0% | ||
| Q4 24 | 2.5% | 7.0% | ||
| Q3 24 | 14.1% | 3.2% | ||
| Q2 24 | 4.3% | -0.2% | ||
| Q1 24 | -21.9% | -15.4% |
资本支出强度ATRCOFIX
| Q4 25 | 1.1% | 4.9% | ||
| Q3 25 | 1.9% | 4.8% | ||
| Q2 25 | 2.0% | 3.5% | ||
| Q1 25 | 1.8% | 3.5% | ||
| Q4 24 | 2.2% | 4.0% | ||
| Q3 24 | 3.1% | 2.7% | ||
| Q2 24 | 2.1% | 4.7% | ||
| Q1 24 | 2.5% | 5.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATRC
| Appendage Management | $45.5M | 32% |
| Openheart | $38.5M | 27% |
| Other | $26.2M | 19% |
| Pain Management | $22.6M | 16% |
| Minimally Invasive | $7.7M | 6% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
